Pharvaris (NASDAQ:PHVS) Shares Gap Up Following Analyst Upgrade

Shares of Pharvaris (NASDAQ:PHVS) gapped up prior to trading on Friday after Oppenheimer raised their price target on the stock from $38.00 to $42.00. The stock had previously closed at $19.10, but opened at $19.57. Oppenheimer currently has an outperform rating on the stock. Pharvaris shares last traded at $19.04, with a volume of 18,391 shares changing hands.

Separately, Wedbush dropped their price objective on shares of Pharvaris from $35.00 to $31.00 and set an “outperform” rating for the company in a research note on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Pharvaris presently has an average rating of “Moderate Buy” and a consensus price target of $33.60.

Institutional Trading of Pharvaris

A number of large investors have recently made changes to their positions in PHVS. Commodore Capital LP bought a new stake in shares of Pharvaris in the fourth quarter valued at about $22,440,000. venBio Partners LLC raised its holdings in shares of Pharvaris by 15.4% in the fourth quarter. venBio Partners LLC now owns 4,919,504 shares of the company’s stock valued at $137,992,000 after acquiring an additional 654,832 shares in the last quarter. Novo Holdings A S raised its holdings in shares of Pharvaris by 47.7% in the second quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock valued at $32,430,000 after acquiring an additional 556,970 shares in the last quarter. Deerfield Management Company L.P. Series C raised its holdings in shares of Pharvaris by 31.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock valued at $26,269,000 after acquiring an additional 335,687 shares in the last quarter. Finally, Blackstone Inc. bought a new position in Pharvaris in the fourth quarter worth about $2,805,000.

Pharvaris Price Performance

The firm has a market capitalization of $606.87 million, a P/E ratio of -7.09 and a beta of -3.10. The stock’s fifty day simple moving average is $17.72 and its 200 day simple moving average is $20.35.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.02). As a group, sell-side analysts forecast that Pharvaris will post -2.58 EPS for the current fiscal year.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.